Introduction
In developing countries, there is an urgent need to enhance the blood and marrow transplantation facilities. Also, it is important to be certain that these procedures can be carried out within the existing infrastructure of hospitals with requisite expertise. India may no longer be regarded a developing country because of its fast growing economy, but with a population of more than a billion, the health services available to the majority are still underdeveloped. Although many hospitals are treating acute leukemias and severe aplastic anemia (SAA), they are hesitant to start allogeneic transplants. A major reason for this is the perceived need to have dedicated units equipped with special air-handling facilities and high-efficiency particulate air (HEPA) filter rooms. 1 Recently, the need for strict isolation has been questioned. 2 There have also been reports of allogeneic HSCT being performed successfully without protective isolation. These studies have been performed in the western world, where the air quality may be cleaner. 3, 4 The present report is based on our experience of the first 40 allogeneic transplants performed in single private rooms without HEPA filter rooms but with strict isolation. It highlights the safety and efficacy outcomes.
Patients and methods

Patients
Patients suffering from diseases potentially curable by allogeneic HSCT were offered BMT or PBSC transplant if they had a family donor who was HLA matched at six antigens by molecular techniques. Both pediatric and adult patients were eligible. Patients had to arrange their own finances, for which recommendations were provided. There is no universal state-funded health-care system in India, and only a minority of people are covered by insurance or their employers. As part of the counseling, patients were informed that the Hematology department of All India Institute of Medical Sciences did not have a dedicated transplant unit with special HEPA filter rooms.
The first 40 consecutive transplants performed from July 2004 to November 2007 are being presented. The analysis is restricted to this period so that the minimum follow-up for all living patients could be more than 100 days.
Methods
Supportive care. As HEPA-filtered rooms are not available in our center, patients were nursed in non-HEPAfiltered air-conditioned single rooms with barrier nursing, wet mopping of rooms twice daily and entry restricted to two attendants. Rooms were fumigated before occupation with a fogging machine using a commercial preparation Eco-shield (marketed by Johnson and Johnson, Mumbai, India) consisting of a formulation of stabilized hydrogen peroxide 11%w/v with 0.01%w/v diluted silver nitrate solution. A 20% solution was used and an aerosol generated to release droplets of 7-20 mm. The machine was run for 40 min and thereafter the room was kept closed for 45 min. Patients were kept in isolation from start of conditioning till engraftment. All persons entering the room changed their footwear, put on a face mask and cap, and washed their hands thoroughly or used antiseptic handwash. Cooked food and boiled then cooled water was allowed. Alternatively, commercially available mineral water of reputable brands was also permitted although these were not tested for bacterial loads. The Bureau of Indian Standards prescribes a zero tolerance of coliforms in 250 ml and the total heterotrophic bacterial plate count limit at 100 CFU/ml at 22 1C in 72 h at nutrient agar, but these standards are not met by many available brands. 5 Patients were encouraged to continue oral intake, and total parenteral nutritional was rarely used. Double lumen Hickman catheters were inserted in adults under local anesthesia by the Hematology physicians. In children, these were inserted under general anesthesia by the surgeons or anesthesiologists.
Conditioning regimens. For aplastic anemia: this consisted of fludarabine 180 mg/m 2 over 6 days þ CY 120 mg/kg over 2 days þ antithymocyte globulin (ATG) over 4 days. Two different ATG preparations were used, based on cost factor: standard preparation was ATGAM (Pharmacia & Upjohn Company, Kalamazoo, MI, USA, marketed by Pfizer Inc., New York, NY, USA) at 30 mg/kg/day and the alternative was the less-expensive Thymogam (Bharat Serums and Vaccines, Mumbai, India) at 40 mg/kg/day. 6 For CML, AML, ALL and myelodysplastic syndrome: BU 16 mg/kg over 4 days þ CY 120 mg/kg over 2 days.
For thalassemia major: BU 16 mg/kg over 4 days þ CY 200 mg/kg over 4 days þ ATG (ATGAM) 90 mg/kg over 3 days.
GVHD prophylaxis consisted of CY (i.v. or oral) twice daily to keep trough levels between 166 and 250 nmol/l (200-300 ng/ml) with MTX i.v. at 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 1. For aplastic anemia, MTX was given on day 1 at 10 mg/m 2 and on days 3 and 6 at 7 mg/m 2 .
Source of stem cells. The preferred source of stem cells was G-CSF-mobilized PBSC. The minimum target cell dose was 3 Â 10 6 cells per kg CD 34 þ cells. If the dose collected was less than 3 Â 10 6 cells per kg, the harvest was repeated the next day to increase the dose, and the second day of infusion was taken as day 0. The cell separator used was the Hemonetics MCS3P or MCSplus. In small donors where PBSC was technically difficult, bone marrow was harvested under anesthesia with a target-nucleated cell dose of 3 Â 10 8 cells per kg. Routine sternal aspiration needles were used and marrow was collected in a blood-collecting bag, using a three-way connection without any online filter. Red cell depletion was performed for major ABO incompatibility. At the time of infusion of marrow, a routine blood transfusion set with a 200 mm filter was used.
Antimicrobial prophylaxis. All patients received oral ciprofloxacin, fluconazole and acyclovir as antibacterial, antifungal and antiviral prophylaxis, respectively. Ciprofloxacin was stopped on neutrophil engraftment and replaced with oral penicillin. Fluconazole was stopped on day þ 30 unless the patient was on steroids for GVHD treatment. Acyclovir was continued for 3 months. Co-trimoxazole was started on day À6, discontinued one day before stem cell infusion and restarted after neutrophil recovery.
Blood component support and growth factors. Hemoglobin was maintained above 90 g/l (9 g/dl) and platelet counts above 20 Â 10 9 /l by irradiated blood and platelet transfusions. The blood bank screens donors as per World Health Organization recommendations. Most of the adult Indian population is seropositive for CMV, so blood donors are not screened for CMV as it is impractical to transfuse CMV-negative blood products. In a study of blood donors, 95% were positive for CMV IgG 7 and in another study of BMT in India, all 214 consecutive transplant recipients and their donors were seropositive for CMV. 8 Leucodepletion was not performed in majority of cases. G-CSF was started 24 h after stem cell infusion and discontinued when the ANC remained above 0.5 Â 10 9 per l on two consecutive days.
Engraftment. Blood counts were performed daily till engraftment. Day of myeloid engraftment was defined as the first of three consecutive days with ANC more than 0.5 Â 10 9 per l. Initially, chimerism facilities were not available and we used blood group change in case of major ABO mismatch or sex chromosome changes in case of sexmismatched transplants to monitor engraftment. Presently, chimerism using short tandem repeat is being used.
Infections. Fever was defined as a single temperature of more than 38.3 1C (101 1F) or more than 38.0 1C (100.4 1F) lasting for more than 1 h. Any febrile episode was treated with broad-spectrum antibiotics. First-line antibiotic cover during conditioning consisted of piperacillin-tazobactam and amikacin þ /À teicoplanin. Imipenem or meropenem was started as first-line antibiotics if fever occurred any time after stem cell infusion and before engraftment. Systemic antifungals were added if fever persisted for 3 days or more while on antibiotic cover or if there was radiological/computed tomography scan suspicion of fungal pneumonia or sinusitis. Antifungals consisted of amphotericin, voriconazole or lipid formulations of amphotericin. All patients and donors were tested for CMV antibodies. Ganciclovir was given as pre-emptive therapy if there was a positive result of pp65 antigen or CMV PCR.
Infections any time during conditioning or within 28 days of transplant were recorded. This period was chosen as most of our aplastic anemia patients were neutropenic at initiation of conditioning, and the neutropenic period is expected to recover by day 28 in patients who engraft.
Criteria for diagnosis of infection included any of the following: fever, positive blood culture, clinical or radiological focus of infection. Most of the patients who received ATG during conditioning developed fever, often accompanied with chills and rigors. As all the aplastic anemia patients were also severely neutropenic, they were started on empirical antibiotics. This might have led to overdiagnosis of infection in these ATG-related fevers.
Statistical methods
Kaplan-Meier survival curves were prepared disease wise.
Results
General
A summary of the first 40 transplants performed is given in Table 1 . The median age was 19 years (range 2.2-46) with 29 male and 11 female participants. The median time of neutrophil engraftment was 10 days (range 8-17). Survival curves are shown in Figure 1 .
Infections
Details of patients who developed infection during conditioning or in the first 28 days of HSCT are given in Table 2 . Fever occurred in 95% patients. The median duration of fever was 5 days (range 1-18). The maximum period of fever was in patients who were infected pretransplant and remained febrile during the conditioning period. In 50% of patients, there was no localization of infection despite fever. In some of these, it is likely that fever was related to ATG infusion. Blood cultures were positive in 17.5% of total cases. Of those with positive blood culture, Gram-negative organisms were isolated in 57% and Gram-positive in 43%. In 15%, there was radiological indication of infection. In one patient of very severe aplastic anemia with computed tomography scan features of sinusitis, biopsy revealed mucormycosis. The infection was present pretransplant. In another patient with AML, computed tomography chest was suggestive of fungal infection pretransplant, but microbiological proof was not obtained. Both underwent transplant while on systemic antifungal therapy.
Fatalities
The 100-day mortality was only one (2.5%), occurring on day þ 66 in a patient of AML who had pretransplant probable fungal pneumonia and later developed severe veno-occlusive disease of the liver. There were eight fatalities after day 100 because of a variety of causes, shown in Table 3 .
Discussion
The recommendation to have special air ventilation systems with point-of-use HEPA filters capable of screening air particles of the size of 0. 3 mm is based on expert opinion rather than any well-designed trials. 2 Before July 2004, transplants were not being performed by our department, Allogeneic transplantation in non-HEPA filter rooms R Kumar et al and many patients potentially curable by allogeneic HSCT succumbed to their illness. As the principal author had experience of performing allogeneic transplants in single isolation rooms, it was decided to start HSCT within the existing infrastructure. In 2004, the first patient was a child with thalassemia major, the second a CML patient who had presented in accelerated phase and the third a boy with SAA who had failed CY therapy. The success of these resulted in an increase in the number of patients, and at present two to three transplants are being performed every month. The initial low mortality and lack of severe infections suggest that allogeneic SCT can be performed in single rooms without HEPA filter even in India despite its dusty climate. The report by Russell et al. 3 suggested that climate that is cold, dry and at a higher altitude can have an important function in low infection rates in patients who were not kept isolated in special rooms. In terms of air pollution, Delhi is considered the most polluted city in the country 9 and despite pollution control measures, the particulate matter in the air remains above permissible limits. 10 Thus, climate and atmosphere cannot be a factor in the low infection rates.
These results cannot also be attributed to a less-intensive conditioning regimen. All our patients underwent myeloablative conditioning, except for the patients of aplastic anemia. Even in this group, the conditioning was more immunosuppressive than the conventional conditioning for aplastic anemia, which consists of CY with or without ATG. As patients with SAA are neutropenic because of their disease per se, they are highly prone to infective complications.
Various factors could have contributed to the low early mortality. We used both antifungal and antibacterial prophylaxis. Although some authorities do not use any antibacterial prophylaxis, there is also an opinion that there is benefit with quinolones. 11 Fluconazole is recommended in allogeneic BMT. 12 In practice, many doctors use prophylaxis. 13 Use of PBSC in most of the cases resulted in early engraftment at a median time of 10 days. With the exception of aplastic anemia, most of our other patients developed severe neutropenia after day þ 3, so the absolute neutropenic period was less than a week.
Another factor for the low infection-related complications may be our antimicrobial policy of using very effective and broad-spectrum antibiotics upfront. The main advantage of using HEPA filter rooms is a reduction in aspergillus infection. 3, 14 Lacking this facility, we anticipated increased aspergillus infection. Therefore, antifungal drugs were started on the third day of fever, rather than on the conventional fifth or seventh day. This was to prevent fungal infections from getting established, with subsequent high mortality. In most cases, if there was no radiological evidence of possible fungal infection, systemic antifungal drugs were stopped on recovery of neutropenia. In actual practice, 47% of patients were not administered any systemic antifungal therapy.
Long-term follow-up of our patients is still limited, but initial trends in the outcome are encouraging. There has been no mortality or relapse in our patients of CML, thalassemia major or myelodysplastic syndrome. In most countries, transplants have been virtually given up in CML with the availability of imatinib and dasatinib. In developing countries, unless these medicines are provided free by the health services or insurance, this lifelong therapy is unaffordable for most patients. In young patients with a low risk of transplant-related mortality, allogeneic transplants remain a reasonable option. SAA constituted the major group of our transplants. We see about 150 aplastic anemia patients annually. Owing to economic reasons, only a minority are able to proceed to transplantation. In the west, the best results are in patients transplanted within 83 days. 15 In our SAA patients, the median time to transplant was 8 months, with only three patients being transplanted Allogeneic transplantation in non-HEPA filter roomsat less than 90 days. Our overall survival of 77.7% in this group of multitransfused patients appears comparable to larger series. 15 Our study is not a comparison between HEPA filter and single isolation rooms, and the number of patients is too small to conclude that HEPA-filtered rooms are not necessary. If we had such a facility, we could have been more judicious in our use of antifungals and antibiotics. Nevertheless, our experience suggests that availability of dedicated BMT units with special air-handling equipment should not be considered a critical and essential precondition for providing allogeneic HSCT to patients who would otherwise succumb to potentially curable hematologic illnesses.
